NSW government seizes $1m of illegal e-cigarette products in 19 weeks

Events
Jun.13.2022

Cancer Council commends ‘zero tolerance’ for unlawful sales

 

Cancer Council NSW has commended the NSW Government’s “zero tolerance” of nicotine e-cigarette sales without a doctor’s prescription, following a major increase in the volume of illegal products seized in 2022 compared with the past two years.

 

Director of Cancer Prevention and Advocacy at Cancer Council NSW, Anita Dessaix, said the surge in illegal product seizures comes only six weeks after Australian National University (ANU) published a landmark study highlighting the extensive harms of e-cigarettes especially to young people.

 

“In the 18 months from July 2020 to the end of last year, $2 million worth of illegal nicotine e-cigarette products was seized – and the government has since seized half as much again in only 19 weeks this year,” Ms Dessaix said.

 

As it stands, the only legal way to access a vape containing nicotine is via a valid doctor’s prescription for those who feel it will aid their quit smoking journey. However, illegal seizure trends are growing exponentially,

 

“We see unlawful e-cigarette use everywhere we look, with young people the main users. Community concern among parents and teachers in particular is rising..

 

“The recently published ANU report showed that the majority of e-cigarette users are young, they are not using e-cigarettes to quit smoking, they are using e-cigarettes with, not instead of, tobacco and those who don’t smoke face a three-fold risk of smoking uptake.

“We congratulate the NSW Government for warning retailers selling e-cigarettes without a valid prescription that they could face fines and even jail for contributing to this crisis.

 

“For the sake of a profit, these merchants are addicting young people to nicotine, they are exposing young people to a three-fold risk of smoking uptake, and they are flouting federal and state laws designed to protect public health.

 

“NSW Government, and its Chief Health Officer, Dr Kerry Chant, have shown great leadership in highlighting the major harms of e-cigarettes and putting the merchants who are contributing to it on notice.”

 

“This is about ensuring that vaping doesn’t undo decades of public health efforts to prevent harm caused by tobacco products”.

Product | PMI Japan Expands ZYN by IQOS Strength Portfolio With Strong Series, Increasing Lineup to 12 Products
Product | PMI Japan Expands ZYN by IQOS Strength Portfolio With Strong Series, Increasing Lineup to 12 Products
Philip Morris Japan (PMJ) has expanded the ZYN by IQOS oral tobacco pouch portfolio in Japan with four new ZYN Strong products, adding a third intensity level alongside the existing Low and Medium ranges. The Strong series first entered selected duty-free channels in Japan on July 1, 2026, before expanding to IQOS stores, the ZYN Online Store and selected tobacco retailers from August 18. The expansion increases the Japanese ZYN by IQOS lineup from eight to 12 products.
Aug.20
Malaysia Nicotine Vape Market Faces Legal Uncertainty Over Tax and Poisons List Ruling
Malaysia Nicotine Vape Market Faces Legal Uncertainty Over Tax and Poisons List Ruling
Malaysia’s Finance Minister Anwar Ibrahim said duties and taxes on nicotine-containing vape products will be determined in line with the Court of Appeal’s ruling on whether liquid or gel nicotine can be exempted from the Poisons List under the Poisons Act 1952, a case that could affect the legal basis for vape taxation, retail sales and future ban policy.
Jun.29
FDA Grants MRTP Orders for 20 ZYN Nicotine Pouches
FDA Grants MRTP Orders for 20 ZYN Nicotine Pouches
The U.S. Food and Drug Administration (FDA) has issued modified risk granted orders to Swedish Match USA for 20 ZYN nicotine pouch products, allowing the already-authorized products to be marketed with a specific claim that using ZYN instead of cigarettes lowers the risk of mouth cancer, heart disease, lung cancer, stroke, emphysema and chronic bronchitis.
Jul.01
China’s Jiangsu Tobacco Monopoly Bureau and Drug Regulator Target Illegal Vape Sales Disguised as Medical Devices, Define Six Violations
China’s Jiangsu Tobacco Monopoly Bureau and Drug Regulator Target Illegal Vape Sales Disguised as Medical Devices, Define Six Violations
China’s Jiangsu Tobacco Monopoly Bureau and Jiangsu Provincial Medical Products Administration have issued a joint notice targeting illegal production and sales of vape products disguised as medical devices. The notice identifies six categories of violations, including obtaining medical licenses through false materials, misusing medical device credentials, expanding production beyond approved scopes, and using medical device-related online platforms to promote or sell vape products. The action is based on China’s tobacco and medical device regulations and aims to strengthen vape oversight and consumer protection.
Aug.04
Reuters Tracks Big Tobacco’s Shift Beyond Cigarettes as Nicotine Pouches Vie for the Next Growth Curve
Reuters Tracks Big Tobacco’s Shift Beyond Cigarettes as Nicotine Pouches Vie for the Next Growth Curve
As cigarette markets face long-term pressure, major tobacco companies are increasingly turning to nicotine pouches in search of growth beyond combustible tobacco. Reuters has examined whether nicotine pouches can become the next strategic growth platform for companies including Philip Morris International, British American Tobacco and Japan Tobacco. PMI strengthened its position through the acquisition of Swedish Match and its ZYN brand, while BAT and JTI continue expanding their own nicotine pouch portfolios. The category has gained attention because of its smoke-free, device-free format, but regulation, youth-use concerns and market scale will determine whether it can become a long-term growth engine.
Regulations
Aug.18 by 2Firsts Perspectives
French Vape Market Under Pressure as Europe’s First Listed Vape Company Kumulus Vape Reports 7.8% H1 Revenue Decline, Retail Sales Rise 41.5%
French Vape Market Under Pressure as Europe’s First Listed Vape Company Kumulus Vape Reports 7.8% H1 Revenue Decline, Retail Sales Rise 41.5%
Kumulus Vape, Europe’s first publicly listed vape company, reported a 7.8% year-on-year decline in first-half 2026 revenue. Amid changing conditions in France’s vape market, the company said channel diversification helped offset pressure, with physical store sales increasing 41.5% year on year. Listed on Euronext Access Paris in 2019 and later transferred to Euronext Growth Paris, Kumulus Vape is viewed as a representative company of Europe’s vape sector. Its performance highlights the industry’s shift from rapid expansion toward more operationally focused growth.
Jul.27